EGFR and non-small cell lung carcinoma: The LUX-Lung 7 trial8 reported statistically significant benefits in progression-free survival (PFS) in patients treated with afatinib compared to those observed following treatment with gefitinib as first-line therapy in NSCLC patients harboring EGFR-activating mutations (HR 0.73).